​

Rigel Pharmaceuticals (RIGL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RIGL Stock Forecast

Rigel Pharmaceuticals (RIGL) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $1.50, with a high of $2.00 and a low of $1.00. This represents a -91.10% decline from the last price of $16.85.

- $6 $12 $18 $24 $30 High: $2 Avg: $1.5 Low: $1 Last Closed Price: $16.85

RIGL Stock Rating

Rigel Pharmaceuticals stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (57.14%), 6 Hold (42.86%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 6 8 Strong Sell Sell Hold Buy Strong Buy

RIGL Price Target Upside V Benchmarks

TypeNameUpside
StockRigel Pharmaceuticals-91.10%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$16.85$16.85$16.85
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25114--6
Mar, 25114--6
Feb, 25114--6
Jan, 25114--6
Dec, 24114--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 17, 2022Piper Sandler$2.00$1.5628.21%-88.13%
Jun 08, 2022Eun YangJefferies$1.00$0.7140.85%-94.07%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 06, 2025CitigroupBuyBuyhold
Mar 05, 2025B. RileyNeutralNeutralhold
Nov 11, 2024CitigroupBuyBuyhold
Sep 03, 2024H.C. WainwrightBuyBuyhold
Aug 07, 2024H.C. WainwrightBuyBuyhold
Dec 02, 2022CitigroupBuyupgrade
Aug 18, 2022H.C. WainwrightBuyBuyhold
Aug 16, 2022Piper SandlerNeutralNeutralhold
Jun 09, 2022BMO CapitalOutperformOutperformhold
Jun 08, 2022JefferiesBuydowngrade

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.76$-1.05$-3.40$-1.44$0.99----
Avg Forecast$-1.72$-1.02$-4.53$-1.70$0.39$1.12$1.87$1.14$1.12
High Forecast$-1.56$-0.92$-4.30$-1.34$0.58$1.56$3.21$1.82$1.13
Low Forecast$-1.87$-1.11$-4.67$-1.88$0.16$0.56$0.93$0.17$1.10
Surprise %2.33%2.94%-24.94%-15.29%153.85%----

Revenue Forecast

$50M $100M $150M $200M $250M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$108.62M$149.24M$120.24M$116.88M$179.28M----
Avg Forecast$108.56M$150.63M$97.78M$114.73M$171.80M$198.85M$228.12M$244.06M$266.78M
High Forecast$115.81M$160.69M$100.02M$115.84M$173.46M$202.15M$228.12M$246.74M$269.37M
Low Forecast$100.46M$139.39M$93.90M$113.31M$169.67M$194.49M$228.11M$241.38M$263.48M
Surprise %0.06%-0.92%22.97%1.88%4.36%----

Net Income Forecast

$-350M $-260M $-170M $-80M $10M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-30.39M$-17.91M$-61.60M$-25.09M$17.48M----
Avg Forecast$-300.00M$-177.99M$-79.04M$-25.09M$3.88M$23.53M$36.95M$17.30M$19.40M
High Forecast$-270.90M$-160.72M$-63.23M$-20.07M$10.16M$27.07M$55.86M$31.69M$19.65M
Low Forecast$-326.07M$-193.45M$-94.84M$-30.11M$2.77M$9.83M$16.22M$2.91M$19.09M
Surprise %-89.87%-89.94%-22.07%-350.53%----

RIGL Forecast FAQ

Is Rigel Pharmaceuticals stock a buy?

Rigel Pharmaceuticals stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rigel Pharmaceuticals is a favorable investment for most analysts.

What is Rigel Pharmaceuticals's price target?

Rigel Pharmaceuticals's price target, set by 14 Wall Street analysts, averages $1.5 over the next 12 months. The price target range spans from $1 at the low end to $2 at the high end, suggesting a potential -91.10% change from the previous closing price of $16.85.

How does Rigel Pharmaceuticals stock forecast compare to its benchmarks?

Rigel Pharmaceuticals's stock forecast shows a -91.10% downside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Rigel Pharmaceuticals over the past three months?

  • April 2025: 16.67% Strong Buy, 16.67% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 16.67% Strong Buy, 16.67% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 16.67% Strong Buy, 16.67% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.

What is Rigel Pharmaceuticals’s EPS forecast?

Rigel Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $1.12, marking a 13.13% increase from the reported $0.99 in 2024. Estimates for the following years are $1.87 in 2026, $1.14 in 2027, and $1.12 in 2028.

What is Rigel Pharmaceuticals’s revenue forecast?

Rigel Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $198.85M, reflecting a 10.92% increase from the reported $179.28M in 2024. The forecast for 2026 is $228.12M, followed by $244.06M for 2027, and $266.78M for 2028.

What is Rigel Pharmaceuticals’s net income forecast?

Rigel Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $23.53M, representing an 34.57% increase from the reported $17.48M in 2024. Projections indicate $36.95M in 2026, $17.3M in 2027, and $19.4M in 2028.